34.70
price down icon1.08%   -0.485
 
loading
전일 마감가:
$35.19
열려 있는:
$35.04
하루 거래량:
149.35K
Relative Volume:
0.54
시가총액:
$975.26M
수익:
-
순이익/손실:
$-69.47M
주가수익비율:
-6.2003
EPS:
-5.5973
순현금흐름:
$-73.92M
1주 성능:
+1.61%
1개월 성능:
+20.20%
6개월 성능:
+54.71%
1년 성능:
+59.61%
1일 변동 폭
Value
$34.65
$35.87
1주일 범위
Value
$31.88
$35.95
52주 변동 폭
Value
$16.54
$38.93

Lenz Therapeutics Inc Stock (LENZ) Company Profile

Name
명칭
Lenz Therapeutics Inc
Name
전화
858-925-7000
Name
주소
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Name
직원
42
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
LENZ's Discussions on Twitter

LENZ을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
LENZ
Lenz Therapeutics Inc
34.65 980.05M 0 -69.47M -73.92M -5.5973
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
464.11 123.00B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
548.26 59.66B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
321.62 41.84B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.77 33.98B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
287.70 27.67B 3.81B -644.79M -669.77M -6.24

Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-14 재개 Piper Sandler Overweight
2025-03-18 개시 TD Cowen Buy
2024-09-27 개시 Raymond James Outperform
2024-08-12 개시 H.C. Wainwright Buy
2024-04-15 개시 Leerink Partners Outperform
2024-04-15 개시 William Blair Outperform
2024-04-10 개시 Citigroup Buy
2024-03-27 개시 Piper Sandler Overweight
2023-02-23 다운그레이드 BofA Securities Neutral → Underperform
2023-02-23 다운그레이드 Cantor Fitzgerald Overweight → Neutral
2023-02-23 다운그레이드 Cowen Outperform → Market Perform
2023-01-25 다운그레이드 BTIG Research Buy → Neutral
2023-01-18 다운그레이드 BofA Securities Buy → Neutral
2023-01-06 다운그레이드 BMO Capital Markets Outperform → Market Perform
2023-01-06 다운그레이드 SVB Leerink Outperform → Mkt Perform
2022-09-15 개시 Cantor Fitzgerald Overweight
2022-06-17 개시 BMO Capital Markets Outperform
2022-04-14 개시 BTIG Research Buy
2022-03-22 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2022-02-18 개시 RBC Capital Mkts Sector Perform
2021-07-20 개시 Morgan Stanley Overweight
2021-07-20 개시 SVB Leerink Outperform
모두보기

Lenz Therapeutics Inc 주식(LENZ)의 최신 뉴스

pulisher
Jul 16, 2025

LENZ Therapeutics, Inc. (LENZ) is a Great Momentum Stock: Should You Buy? - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

what makes lenz therapeutics inc. stock price move sharplyVolume Spike Monitors - Newser

Jul 16, 2025
pulisher
Jul 15, 2025

What makes LENZ Therapeutics Inc. stock price move sharplyFree Top-Rated Stock Analysis - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why LENZ Therapeutics Inc. stock attracts strong analyst attentionReliable High Profit Alerts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How LENZ Therapeutics Inc. stock performs during market volatilityLow Risk Consistent Winners - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Does LENZ Therapeutics, Inc. (LENZ) Have the Potential to Rally 30.86% as Wall Street Analysts Expect? - Yahoo Finance

Jul 15, 2025
pulisher
Jul 14, 2025

Versant funds sell $6.5 million in Lenz Therapeutics (LENZ) - Investing.com Australia

Jul 14, 2025
pulisher
Jul 14, 2025

Versant funds sell $6.5 million in Lenz Therapeutics (LENZ) By Investing.com - Investing.com South Africa

Jul 14, 2025
pulisher
Jul 14, 2025

Leerink Partnrs Has Bearish Outlook for LENZ FY2028 Earnings - Defense World

Jul 14, 2025
pulisher
Jul 11, 2025

LENZ Therapeutics Shares Soar 4.93% on Strategic Partnership, Regulatory Milestone - AInvest

Jul 11, 2025
pulisher
Jul 09, 2025

LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada - VisionMonday.com

Jul 09, 2025
pulisher
Jul 09, 2025

LENZ and Théa partner on Canadian commercialization of presbyopia eye drop - Eyes On Eyecare

Jul 09, 2025
pulisher
Jul 08, 2025

LENZ Therapeutics and Laboratoires Théa partner to commercialize LNZ100 for presbyopia in Canada - Ophthalmology Times

Jul 08, 2025
pulisher
Jul 07, 2025

Lenz Therapeutics stock gains as William Blair reiterates Outperform By Investing.com - Investing.com Nigeria

Jul 07, 2025
pulisher
Jul 07, 2025

Lenz Therapeutics stock gains as William Blair reiterates Outperform - Investing.com

Jul 07, 2025
pulisher
Jul 07, 2025

LENZ and Théa ink $70 million licensing deal for presbyopia treatment - Investing.com India

Jul 07, 2025
pulisher
Jul 07, 2025

LENZ Therapeutics and Laboratoires Théa Announce Exclusive - GlobeNewswire

Jul 07, 2025
pulisher
Jul 07, 2025

$70M Licensing Deal: LENZ Eyes Canadian Market with Breakthrough Presbyopia Treatment - Stock Titan

Jul 07, 2025
pulisher
Jul 03, 2025

LENZ Therapeutics: A Pivotal Moment for Presbyopia and Potentially Transformative Returns - AInvest

Jul 03, 2025
pulisher
Jul 01, 2025

LENZ Therapeutics: Presbyopia Eyedrops Look Promising (NASDAQ:LENZ) - Seeking Alpha

Jul 01, 2025
pulisher
Jun 30, 2025

LENZ Therapeutics, Inc.(NasdaqGS: LENZ) dropped from Russell Microcap Value Index - MarketScreener

Jun 30, 2025
pulisher
Jun 16, 2025

LENZ Therapeutics: Ready To Test Its Potential (NASDAQ:LENZ) - Seeking Alpha

Jun 16, 2025
pulisher
Jun 10, 2025

LENZ Therapeutics reports results of stockholder vote By Investing.com - Investing.com Nigeria

Jun 10, 2025
pulisher
Jun 10, 2025

LENZ Therapeutics reports results of stockholder vote - Investing.com

Jun 10, 2025
pulisher
Jun 10, 2025

LENZ Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks

Jun 10, 2025
pulisher
Jun 10, 2025

Citi maintains Buy rating, $45 target on LENZ Therapeutics stock By Investing.com - Investing.com South Africa

Jun 10, 2025
pulisher
Jun 10, 2025

Citi maintains Buy rating, $45 target on LENZ Therapeutics stock - Investing.com

Jun 10, 2025
pulisher
Jun 10, 2025

Two Sigma Investments LP Has $493,000 Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Transcript : LENZ Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 04 - MarketScreener

Jun 09, 2025
pulisher
Jun 07, 2025

Bank of America Corp DE Boosts Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

LENZLENZ Therapeutics Reports Third Quarter 2024 Financial Results - mx.advfn.com

Jun 05, 2025
pulisher
Jun 05, 2025

Jane Street Group LLC Cuts Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

BNP Paribas Financial Markets Sells 859 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Lenz Therapeutics’ Earnings Call Highlights Strong Outlook - MSN

Jun 03, 2025
pulisher
Jun 02, 2025

Deutsche Bank AG Purchases 4,370 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Stock Holdings Boosted by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Holdings Decreased by Ameriprise Financial Inc. - Defense World

Jun 01, 2025
pulisher
Jun 01, 2025

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of “Buy” by Analysts - Defense World

Jun 01, 2025
pulisher
May 30, 2025

LENZ Therapeutics Prepares for LNZ100 Launch - TipRanks

May 30, 2025
pulisher
May 29, 2025

7,447 Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Purchased by D. E. Shaw & Co. Inc. - Defense World

May 29, 2025
pulisher
May 27, 2025

LENZ Therapeutics May 2025 slides: presbyopia treatment nears FDA decision - Investing.com Canada

May 27, 2025
pulisher
May 27, 2025

LENZ Therapeutics to Present at Upcoming Investor Conferences - The Manila Times

May 27, 2025
pulisher
May 27, 2025

LENZ Therapeutics Showcases Revolutionary Eye Drop Treatment at Goldman Sachs, Jefferies Healthcare Events - Stock Titan

May 27, 2025
pulisher
May 23, 2025

Northern Trust Corp Raises Stock Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World

May 23, 2025
pulisher
May 20, 2025

Asia Deal Watch: Lilly Partners With Rznomics On Hearing Loss - insights.citeline.com

May 20, 2025
pulisher
May 14, 2025

Transcript : LENZ Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 09 - marketscreener.com

May 14, 2025
pulisher
May 13, 2025

Tower Research Capital LLC TRC Has $54,000 Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World

May 13, 2025
pulisher
May 13, 2025

Taiwan's Lotus Pharma inks $125 M deal with LENZ Therapeutics to commercialise presbyopia treatment - BioSpectrum Asia

May 13, 2025
pulisher
May 12, 2025

LENZ Therapeutics and Lotus partner for LNZ100 distribution in Asia - World Pharmaceutical Frontiers

May 12, 2025
pulisher
May 12, 2025

LENZ and Lotus Pharmaceutical collaborate to commercialise presbyopia treatment - Yahoo Finance

May 12, 2025
pulisher
May 12, 2025

Raymond James Financial Inc. Takes $245,000 Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World

May 12, 2025

Lenz Therapeutics Inc (LENZ) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Lenz Therapeutics Inc 주식 (LENZ) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Versant Venture Capital VI, L.
10% Owner
Jun 27 '25
Sale
30.46
200,000
6,093,000
1,767,275
Versant Venture Capital VI, L.
10% Owner
Jun 20 '25
Sale
30.25
133,924
4,051,201
1,967,275
Versant Venture Capital VI, L.
10% Owner
Jun 20 '25
Sale
30.35
100,877
3,061,617
1,047,912
Versant Venture Capital VI, L.
10% Owner
Jun 18 '25
Sale
29.95
100,000
2,995,000
1,148,789
Versant Venture Capital VI, L.
10% Owner
Jun 10 '25
Sale
29.00
350,000
10,150,000
1,248,789
Olsson Shawn
Chief Commercial Officer
Apr 09 '25
Option Exercise
2.08
1,400
2,912
4,733
Schimmelpennink Evert B.
President, CEO and Secretary
Mar 07 '25
Option Exercise
1.04
4,200
4,368
49,200
Olsson Shawn
Chief Commercial Officer
Dec 16 '24
Option Exercise
2.08
3,333
6,933
3,333
Schimmelpennink Evert B.
President, CEO and Secretary
Jul 22 '24
Option Exercise
1.04
45,000
46,800
45,000
$22.00
price up icon 3.69%
$35.60
price down icon 2.49%
$104.55
price down icon 0.21%
$28.27
price up icon 16.05%
$112.08
price down icon 0.37%
biotechnology ONC
$279.16
price up icon 3.51%
자본화:     |  볼륨(24시간):